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Abstract. Gastrinoma, an infrequent diagnosis in middle-aged dogs, occurs with nonspecific gastrointestinal
morbidity. Laboratory tests can yield a presumptive diagnosis, but definitive diagnosis depends on histopathology and
immunohistochemistry. We describe a malignant pancreatic gastrinoma with lymph node metastases and corresponding
Zollinger–Ellison syndrome in a Mexican gray wolf (Canis lupus baileyi) and review this endocrine neoplasm in domestic
dogs. A 12-y-old, captive, male Mexican gray wolf developed inappetence and weight loss. Abdominal ultrasonography
revealed a thickened duodenum and peritoneal effusion. Two duodenal perforations were noted on exploratory celiotomy
and were repaired. Persisting clinical signs led to a second celiotomy that revealed a mesenteric mass, which was diagnosed
histologically as a neuroendocrine carcinoma. During the following 16 mo, the wolf received a combination of H2-receptor
antagonists, proton-pump inhibitors, gastroprotectants, and anti-emetics, but had recurrent episodes of anorexia, nausea, acid
reflux, and remained underweight. Worsening clinical signs and weakness prompted euthanasia. The antemortem serum
gastrin concentration of 414 ng/L (reference interval: 10–40 ng/L) corroborated hypergastrinemia. Autopsy revealed a mass
expanding the right pancreatic limb; 3 parapancreatic mesenteric masses; duodenal ulcers; focal duodenal perforation with
septic fibrinosuppurative peritonitis; chronic-active ulcerative esophagitis; and poor body condition. The pancreatic mass
was diagnosed histologically as a neuroendocrine carcinoma and the parapancreatic masses as lymph node metastases.
Immunohistochemistry of the pancreatic mass was positive for gastrin and negative for glucagon, insulin, pancreatic
polypeptide, serotonin, somatostatin, and vasoactive intestinal peptide.
Key words: Canis lupus baileyi; dogs; gastrin; gastrinoma; Mexican gray wolf; neuroendocrine tumor; ulcer; Zollinger–
Ellison syndrome.
The Mexican gray wolf (Canis lupus baileyi) is a federally
protected endangered carnivore listed under the Endangered
Species Act since 1976, when the species was nearly extinct.5
Between 1977 and 1980, the Mexican Wolf Species Survival
Plan (MWSSP) established a breeding population, which in
2014 numbered 248 animals distributed among 55 facilities.5
Because of captive-breeding and reintroduction, as per the
U.S. Fish & Wildlife Service Ecological Services of the
Southwest Region (https://www.fws.gov/southwest/es/mexicanwolf/reintroproj.html), by the end of 2016, there were
113 wolves distributed among 23 packs in the wild.
In December 2014, a captive-born 12-y-old intact male
Mexican gray wolf, housed at a facility involved in the
MWSSP, was presented to staff veterinarians because of
inappetence and weight loss of 5.5 kg over the course of 15
mo. Abdominal radiographs were unrewarding. The animal
was sedated for abdominal ultrasonography, which revealed
a thickened duodenum and peritoneal effusion. An exploratory celiotomy allowed detection and repair of 2 duodenal
perforations. Persisting clinical signs led to a second celiotomy that revealed a 4-cm mesenteric mass, which was diagnosed histologically as a suspected neuroendocrine

carcinoma. Over the next 16 mo, the wolf was maintained on
famotidine and omeprazole, and inconsistently received
sucralfate, pantoprazole (Protonix, Pfizer, Philadelphia, PA),
and maropitant (Cerenia, Zoetis, Kalamazoo, MI). During
this time, the animal was intermittently anorexic and would
chronically lick his lips causing caretakers to suspect nausea
and acid reflux. Progressive anorexia, suspected chronic acid
reflux, and lethargy prompted euthanasia.
At autopsy, the animal had moderate generalized muscle
atrophy, scant-to-moderate adipose stores, and was dehydrated. There was multisegmental chronic-active ulcerative
esophagitis. The abdominal cavity contained 200 mL of
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Figures 1–4. Pancreatic gastrinoma and Zollinger–Ellison syndrome in a Mexican gray wolf (Canis lupus baileyi).
Figure 1. Focally expanding the right pancreatic limb and abutting the duodenum is a gastrinoma (*). In the adjacent mesentery, there
are 2 lymph node metastases (x). There is a focal perforating ulcer (arrow) with bile-stained adipose tissue located 13 cm distal to the pylorus
on the duodenal antimesenteric border. Inset: cross-section of the pancreatic gastrinoma.
Figure 2. The gastric pylorus has an undulating mucosa thickened by mucus cell hyperplasia and hypertrophy and with scattered
lymphocytes in the lamina propria. H&E.
Figure 3. Neoplastic cells that infiltrate the pancreas are arranged in packets typical of a neuroendocrine carcinoma. H&E.
Figure 4. Neoplastic cells that infiltrate the pancreas have strong cytoplasmic staining for gastrin. Gastrin immunohistochemistry, DAB
chromogen, hematoxylin counterstain.

dark-brown fluid, and peritoneal surfaces were roughened
with fibrin and reactive fibrovascular tissue consistent with
peritonitis. Segmentally, the duodenum and the proximal
jejunum were uniformly dilated up to 6 cm in circumference,
and 13 cm distal to the pylorus, on the antimesenteric border,
the duodenum was focally perforated. The serosal defect was
stained with bile, and covered by fibrin, edema, and hemorrhage. The duodenal mucosa, extending for 25 cm, had multifocal, <0.5 cm diameter ulcers. The lumen contained
bile-stained digesta and blood clots. Focally expanding the
right pancreatic limb, 6 cm from the right and left pancreatic
junction, was a 3.5 × 3 × 2 cm firm mass that was moderately
well demarcated and mottled white-to-gray to dark-red on
cross-section (Fig. 1). Within the mesentery adjacent to the
pancreatic limbs, there were 3 firm masses, which measured
2.5 cm3, 7.5 × 3.5 × 2.5 cm, and 4.5 × 3 × 2.5 cm (Fig. 1). On
cross-section, all masses were similar to the pancreatic mass.
Additional findings included moderate leptomeningeal
fibrosis, splenic contraction, focal adrenal gland cortical
nodular hyperplasia, hepatic nodular hyperplasia with glycogen-type vacuolation, and gastric mucosal hyperplasia
(Fig. 2). The pancreatic mass and the mesenteric masses

were histologically similar. Adjacent to the opening of the
common bile duct was a highly cellular and infiltrative multilobular neuroendocrine neoplasm dissected by thick
fibrous connective tissue (Fig. 3). The mass disrupted and
replaced pancreatic acini, parapancreatic adipose tissue, and
the duodenal serosa and muscularis externa. Neoplastic
cells were arranged in packets and rosettes separated by thin
fibrovascular tissue. The cells had poorly defined borders,
eosinophilic loosely granular cytoplasm, and round-toovoid to notched nuclei with coarse chromatin. The mitotic
count was 3 per ten 400× high-power fields. There was
infrequent karyomegaly. In the adjacent stroma, there was
chronic hemorrhage. The mesenteric masses contained similar neoplastic cells with necrosis, and the masses replaced
and compressed residual lymphoid tissue, indicating that
these masses were lymph node metastases. Rare clusters of
similar neoplastic cells occupied hepatic sinusoids.
Immunohistochemistry for gastrin, glucagon, insulin,
pancreatic polypeptide, serotonin, somatostatin, and vasoactive intestinal peptide was performed on the pancreatic mass
as described previously.4,17 The mass was negative for all
hormones except for strong multifocal cytoplasmic gastrin
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immunoreactivity (Fig. 4), which confirmed the neoplastic
cells to be gastrin-producing.13
Gastrin concentration of 414 ng/L was determined in the
wolf’s serum collected prior to euthanasia (125I radioimmunoassay; Endocrine Diagnostic Laboratory [EDL], Michigan
State University, East Lansing, MI).16 Although a serum gastrin reference interval (RI) is lacking for the Mexican gray
wolf, we presume that the levels are similar to those reported
in dogs. In dogs, the baseline serum gastrin concentration varies among reports, likely because of different assays, and is
described as a range of 10–40 ng/L,16 66–76 pg/mL,18 23–104
pg/mL,18 20–100 pg/mL,18 27–85 pg/mL,6 45–98 pg/mL,6 or
as a mean of 40 pg/mL19 or 71 pg/mL.3 In the case of our
wolf, the gastrin level was ~10 times the higher end of the
canine RI (10–40 ng/L) used by the EDL. In dogs with gastrinoma, serum gastrin concentrations are typically >3 times the
upper end of the RI, but more specific values are lacking
given the rarity of reported cases.21 The therapeutic use of
H2-receptor antagonists and proton-pump inhibitors can
falsely increase serum gastrin, but studies in healthy dogs
have concluded that gastrin concentrations rarely exceed 3
times the upper end of the RI (10–40 ng/L in that study);
therefore, therapy-related fluctuations of serum gastrin are
unlikely to be confounded with a functional gastrinoma.16
Autopsy, histopathology, immunohistochemistry, and
serum gastrin levels in the wolf in our study confirmed a
diagnosis of malignant pancreatic gastrinoma with metastasis to regional lymph nodes, rare tumor microemboli in
hepatic sinusoids, and secondary duodenal peptic ulcers as a
result of Zollinger–Ellison syndrome. One ulcer was transmural and had resulted in septic suppurative peritonitis. The
clinical suspicion of chronic acid reflux was corroborated by
the presence of chronic-active ulcerative esophagitis.
Gastrinoma is a rarely reported neuroendocrine tumor that
is responsible for Zollinger–Ellison syndrome, which is
characterized by gastric acid hypersecretion, upper gastrointestinal ulceration, and non-beta islet cell tumors.18 The syndrome was first described in a dog in 1976,18 and has been
reported mostly in domestic dogs,21 a few cats,21 and now in
a Mexican gray wolf. Affected dogs are middle-aged (range:
3.5–12 y; mean: 8.2 y) without a breed predisposition, and
females may be overrepresented.21 The tumor typically
involves the pancreatic islets,14 but has also been reported in
the duodenal wall at the level of the major duodenal papilla,20
in the liver,13 in the mesenteric root,2 and in parapancreatic
lymph nodes,10 sometimes without a detected pancreatic
mass, although autopsies were not always performed. The
predilection of this tumor for the pancreas is interesting
given that the adult canine pancreas lacks gastrin-producing
cells.13 However, gastrin-producing cells are present in the
pancreas of the developing fetus and neonate, and in the
adult duodenum and gastric antrum.13 Theories to explain
how gastrin-producing neoplasms develop in pancreatic
islets are multiple and include: the translocation of gastrinproducing cells from the duodenum or gastric antrum to the
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pancreatic islets during fetal development; the differentiation
of pluripotent cells, or nesidioblasts, within the pancreatic
islets to gastrin-producing cells or G cells; and de-differentiation from an existing islet pancreatic endocrine cell into a
gastrin-producing cell.13 Gastrinoma tumor cells are reported
to have cytoplasmic granules characteristic of those in delta
cells.1
Patients with functional gastrinomas develop hypergastrinemia that results in nonspecific signs of gastrointestinal
disease. The pathophysiology involved is a perturbed gastric
pH regulatory feedback loop. Normally, gastrin-producing
cells or G cells of the distal part of the stomach produce controlled amounts of gastrin that are essential for gastrointestinal system function.12 The anticipation of eating or gastric
distension or an ingested meal (e.g., protein or high stomach
pH) leads to gastrin release into the blood stream, which
stimulates parietal cells to increase gastric acid production,
thus causing a decrease of gastric pH.12,18 To avoid gastric
hyperacidity, G cells closely monitor the pH of the distal part
of the stomach, and once the pH reaches a critical point (pH
of 1–2),12 the release of gastrin is inhibited. Consequently,
the stimulus to produce gastric acid is removed, and the
stomach pH stabilizes.12 This gastrin-stomach pH regulatory
feedback loop is a major mechanism that protects against
acid-induced mucosal damage. In instances of abnormal and
uncontrolled hypergastrinemia, such as occurs with a functional gastrinoma, the regulatory feedback loop is perturbed
and rendered ineffective at stabilizing stomach pH. Therefore, highly acidic stomach contents may empty into the duodenum or may be expelled through the esophagus. Duodenal
acidification likely activates a second protective mechanism,
the intestinal negative feedback loop, which relies on neuronal reflexes and secretin to suppress gastric acid production
and delay gastric emptying.12 The sequelae of hypergastrinemia are gastric acid hypersecretion and gastric mucosal
hyperplasia.18,21
Common clinical signs are vomiting, weight loss, depression, lethargy, anorexia, and diarrhea;21 in those patients with
gastrointestinal ulceration, which is the majority,21 there may
be hematemesis, melena, hematochezia, abdominal pain,
anemia, fever, leukocytosis, elevated urea, hypoalbuminemia, polydipsia, and electrolyte abnormalities.8–10,15,18 Other
patients, including the wolf in our study, may develop ulcerative esophagitis related to acid reflux favored by a delay in
gastric emptying and chronic regurgitation.8,18,19,21 Less
often, patients have steatorrhea18 or extraluminal bile duct
obstruction.20 Because of the frequency of gastrointestinal
ulceration, perforation and peritonitis are common.21
Diagnosing gastrinoma in a patient is complicated by
nonspecific clinical findings, the rarity of the tumor, the
small size of the tumor, and the variable usefulness of imaging and endoscopy. The clinical signs, physical exam, and
the minimum database (complete blood count, biochemistry)
may suggest gastrointestinal disease, but even so, the differential diagnosis remains broad.9 Abdominal radiographs are
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usually unremarkable unless there is perforation.10,15 Contrast-enhanced radiographs may show gastric wall thickening, complete pyloric obstruction, gastroduodenal ulceration,
or increased small bowel transit time.21 Abdominal ultrasonography may identify a pancreatic mass or metastases,1 but
more often it is unrewarding given the usual small tumor
size.9,10,15 More advanced imaging modalities, such as computed tomography, will increase sensitivity and may visualize neoplastic masses that will require further investigation.21
Endoscopy, with endoscopic biopsies, is commonly used
and can detect pyloric antrum hypertrophy, pyloric stenosis,
gastrointestinal ulceration, hemorrhage, and inflammation.
This approach is unlikely to diagnose gastrinoma and may
result in an erroneous diagnosis of inflammatory bowel
disease.6,10,11,15 In at least 3 cases, endoscopic biopsies revealed
ulcerative inflammation followed by an exploratory celiotomy
that detected a pancreatic gastrinoma,8 a pancreatic gastrinoma with hepatic metastasis,19 or a metastatic gastrinoma.10
Although celiotomy is an invasive procedure, exploratory
celiotomy for biopsy collection and immunohistochemistry
may be the best diagnostic approach. This approach was used
successfully in at least 9 cases.1,7,8,10,13,20 Other useful laboratory tests include a measure of basal gastric acid secretion, a
measure of serum gastrin concentration, and provocative
testing of gastrin secretion with intravenous secretin or calcium gluconate.9,21 Provocative testing is particularly useful
in cases of suspected gastrinoma in which serum gastrin levels are normal-to-borderline.10,15
Although such laboratory tests may aid in diagnosis, in
addition to documenting hypergastrinemia, a definitive diagnosis of gastrinoma is based on histologic evidence of a pancreatic islet cell tumor with neoplastic cells immunoreactive
for gastrin.21 Hypergastrinemia alone is insufficient to diagnose a gastrinoma, because elevated basal serum gastrin may
accompany renal failure, gastric outflow obstruction, hypochlorhydria, atrophic gastritis, small intestinal resection, gastric dilation and volvulus, chronic gastritis, liver disease,
immunoproliferative enteropathy of Basenji dogs, and certain therapeutic drugs.15,21 Although immunohistochemistry
or radioimmunoassay of tumor tissue extracts can confirm
the presence of gastrin in the tumors, it fails to show that the
hormone is being secreted in excess into the circulation.21
Compatible clinical signs and lesions can correlate with a
functional gastrinoma, but documenting concomitant hypergastrinemia is more convincing.
Treatment of canine gastrinoma is difficult and palliative,
and clinicians resort to a combination of surgical intervention and long-term medical therapy.15 Early surgical intervention has the advantage of making a final diagnosis and
beginning treatment, but because of the likelihood that surgical resection will be incomplete, medical management is
important and depends on drugs that reduce gastric acid
secretion and treat gastrointestinal ulceration, while correcting fluid and electrolyte losses.21 Proton-pump inhibitors
such as omeprazole, alone or in combination, appear to be a
good choice for medical management.2,14

Following a diagnosis of gastrinoma, canine patients
have a guarded-to-poor prognosis, in part because metastasis to the liver and regional lymph nodes has already
occurred in 85% of cases.10,18,21 Canine patients receiving
combined treatment are reported to survive up to 18 mo,21
although 1 patient treated indefinitely with omeprazole
was asymptomatic and survived for at least 24 mo,2 and
another receiving ranitidine, omeprazole, and sucralfate
survived for 26 mo.14 Patients were often euthanized upon
diagnosis or following the recurrence of treated disease,
some died before a diagnosis was made,11 and others died
from complications of the disease, including septic peritonitis from intestinal perforation.6,18
The disease progression of the wolf in our study mirrored what is described in domestic dogs diagnosed with
gastrinoma. The wolf had nonspecific clinical signs, and
initial bloodwork and imaging suggested gastrointestinal
disease. Two exploratory celiotomies followed, which
revealed duodenal ulcers and a mesenteric mass suspicious
of a neuroendocrine carcinoma. The animal was medically
managed until it was euthanized because of declining
health. Autopsy and ancillary testing resulted in a definitive
diagnosis of malignant gastrinoma, which had caused longstanding morbidity that included multiple duodenal ulcers,
2 instances of duodenal perforation, gastric mucosal hyperplasia, and reflux esophagitis. It is believed that the primary
gastrinoma was the focal mass in the right pancreatic limb
adjacent to the common bile duct. This location appears to
be a frequent site in dogs,21 and its proximity to the opening
of the bile duct favors one of the elaborated theories of the
origin of pancreatic gastrinomas within the “gastrinoma triangle”.13 This area is delimited by the common and cystic
bile ducts superiorly, the junction of the body and the tail of
the pancreas medially, and the junction of the second and
third segments of the duodenum inferiorly.13 In humans, the
development of gastrin-producing tumors in this area is
thought to originate, in part, from ectopic gastrin-producing cells.13
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